Home » Psychology news » Alkermes Announces FDA Approval Of VIVITROL® For Prevention Of Relapse To Opioid Dependence
Alkermes Announces FDA Approval Of VIVITROL® For Prevention Of Relapse To Opioid Dependence
October 16, 2010 by NewsBot
Alkermes, Inc. (NASDAQ: ALKS) announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL® (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL is now the first and only non-narcotic, non-addictive, once-monthly medication approved for the treatment of opioid dependence...